NSAV Announces the Payoff of Asher Enterprise Notes From

New Post Public Reply Private Reply Replies (0) Message Board
aliangel
NSAV Announces the Payoff of Asher Enterprise Notes From 2013 and 2014, and Assures Shareholders That NSAV Will Not Be Restructuring the Company With a Reverse Split for the Foreseeable Future
Marketwired Net Savings Link, Inc.
19 hours ago


Related Quotes
NSAV
0.0001
-50.00%
Net Savings Link, Inc. Watchlist
0.0001-0.0001(50.00%)
OTC Markets11:04 AM EST

NET SAVINGS LINK, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events EDGAR Online 3 mths ago
NET SAVINGS LINK, INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online 3 mths ago
More
PORT JEFFERSON, NY--(Marketwired - Feb 23, 2015) - Net Savings Link, Inc. (OTC PINK: NSAV) today has announced through its CEO, Steven Baritz, the payoff of over $230,000 in convertible notes that were due to Asher Enterprises, Inc. Mr. Baritz said, "I wanted to extend my deepest appreciation to our shareholders in the continued confidence that they have maintained since I became the CEO of NSAV in June, 2014." Mr. Baritz continued, "Since the commencement of our new management team in June 2014, we have paid off nearly $230,000 of the convertible notes that we inherited from the previous directors, including notes that defaulted on May 31, 2014, which predated our current management team. Six notes from 2013, including a $39,000 default fee, were included in this payoff amount, and 2 notes from early 2014 (which were prior to the current management team) were also nearly paid off, leaving an approximate balance as of this writing of only $2,250."

"I wanted to address the significant concern that has been raised among many of our shareholders with respect to a restructuring of the company via a reverse split option," said Baritz. "NASV does not see a reverse split as a viable option for us for the foreseeable future in the upcoming year," he said. Mr. Baritz continued, "We recognize the challenges that we have, and I feel that our best strategy would incorporate a policy of returning equity to the company by using various merger and acquisition opportunities that we are currently entertaining to create revenue and profits for NSAV, in lieu of a restructuring model via a reverse split of the current share structure. Although NSAV would always reserve the right to include a reverse split as an available option, its use would only be used if all other options and resources were exhausted," Baritz said.

Mr. Baritz also addressed the progress of the pending merger with Bella Vida Brands, Inc. "NSAV is currently evaluating the detailed financial statements for the past 3 years that were presented to NSAV by Bella Vida Brands, Inc., and upon the conclusion of this evaluation, NSAV will then determine the terms and conditions of the merger, and will always ensure that the assets of NSAV and Global Distribution, Inc. are protected. I have asked our shareholder and asset relations manager, David Pecoraro, to identify other companies and market sectors that NSAV can target for additional revenue potential for this upcoming calendar year, so that we can have a variety of diversified business interests that will insulate us from downturns in a single market sector," said Baritz.

"Look for additional news as we release our 10K in March 2015. We have sent the 10K documents to our accounting and auditing firms, and we are waiting for the conclusion of the audit for release," said Baritz.

About Net Savings Link, Inc.
Net Savings Link, Inc. owns and operates a wholly owned subsidiary, Global Distribution Corporation, a distribution company that markets and distributes products in varying industries including the supplement, wellness and natural remedies markets. People interested in learning more about Global Distribution should check back with the company at its website, www.Globaldistributioncorp.net.

DISCLAIMER: This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information contained in this Press Release including such forward-looking statements.
Contact:

David Pecoraro
Shareholder Relations Director
Email: DavidPecoraro@rocketmail.com
Tel : 814-418-6648
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

TSA PreCheck Study Reveals Time Savings and Travel Insights

Updated Category News Views 379

Understanding TSA PreCheck's Impact on Travelers The latest survey reveals some interesting insights about TSA PreCheck, especially concerning the time savings that members experience at security checkpoints. Conducted by Upgraded Points, this enlightening study assessed the experience of over 1,500 travelers to evaluate the true advantages of holding a TSA PreCheck...

Continue Reading
Intermap Technologies Enhances Geospatial Solutions with New Offering

Updated Category News Views 217

Intermap Technologies Announces New Prospectus Supplement DENVER – Intermap Technologies Corporation (TSX: IMP; OTCQB: ITMSF), a recognized leader in 3D geospatial products and intelligence solutions, has filed a prospectus supplement in the context of a strategically planned public offering. This initiative signifies a promising step forward, with the company aiming to...

Continue Reading
Urgent Investor Notice: Humacyte Legal Claims Investigation

Updated Category News Views 94

Critical Deadline for Humacyte Investors Approaches As time runs short, investors in Humacyte, Inc. (NASDAQ: HUMA) should pay attention. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating claims on behalf of investors who have suffered losses exceeding $75,000 due to potential violations in federal securities laws. Understanding Your...

Continue Reading
Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab

Updated Category News Views 226

Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab Natalie Bartholomew, a highly recognized advocate for women in financial services, will be the featured speaker for the Women in Banking session at Alkami Co:lab 2026. Her expertise and passion are expected to inspire attendees and foster discussions around women's roles in the financial sector. Alkami...

Continue Reading
Investors Anticipate Strong Earnings from OPAL Fuels Soon

Updated Category News Views 161

OPAL Fuels Earnings Report Insights OPAL Fuels OPAL is preparing to release its quarterly earnings report soon, and investors are keenly interested in the results. As the anticipated date for this report approaches, it is essential for investors to stay informed and understand what the expectations are. Projected Earnings Overview Analysts project that OPAL Fuels will...

Continue Reading